Literature DB >> 15823813

Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma.

Yi-Rong Li1, Jian-Ming Wu, Lin Wang, Xiang Huang, Jie Shi, Li-Hua Hu.   

Abstract

CONCLUSIONS: Upregulation of hTERT mRNA plays an important role during the occurrence and development of laryngeal squamous cell carcinoma. Most hTERT mRNA in plasma from patients with laryngeal squamous cell carcinoma is derived from tumour cells; moreover, the determination of plasma hTERT mRNA contributes to tumour diagnosis and the observation of curative effect.
OBJECTIVES: To establish a real-time fluorescent reverse transcriptase polymerase chain reaction (RT-PCR) and to quantitate the level of human telomerase reverse transcriptase (hTERT) mRNA in carcinoma tissue and plasma from patients with laryngeal squamous cell carcinoma. We also wished to evaluate the role that hTERT mRNA expression plays during the occurrence and development of laryngeal squamous cell carcinoma, to probe the correlation between the expression level and the clinical and pathological parameters and to investigate the value of the determination of plasma hTERT mRNA in tumour diagnosis and the observation of curative effect.
MATERIAL AND METHODS: A real-time fluorescent RT-PCR and a Lightcycler PCR system were used to quantitate the expression level of hTERT mRNA.
RESULTS: The expression levels of hTERT mRNA (NhTERT) from laryngeal squamous cell carcinoma tissue and corresponding adjacent non-cancerous tissue were 62.6 +/- 21.7 and 3.5 +/- 1.9, respectively. NhTERT was significantly elevated in laryngeal squamous cell carcinoma tissue, rising to 17.9-fold on average, but there was no significant correlation between NhTERT and either tumour location, differentiation degree, T grade or N grade. For healthy examinees, NhTERT in plasma was 1.3 +/- 0.9, compared to 13.1 +/- 9.4 and 9.3 +/- 5.8 in patients with laryngeal squamous cell carcinoma examined before and 2 days after surgery, respectively. Compared to healthy examinees, NhTERT in plasma from patients with laryngeal squamous cell carcinoma was significantly elevated; moreover, 2 days after surgery, NhTERT in plasma had decreased significantly in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823813     DOI: 10.1080/00016480410024451

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  5 in total

1.  Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.

Authors:  Kawin Leelawat; Surang Leelawat; Thawee Ratanachu-Ek; Somboon Trubwongchareon; Jerasak Wannaprasert; Saad Tripongkaruna; Suchart Chantawibul; Panadda Tepaksorn
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

2.  Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis.

Authors:  Aristeidis Chrysovergis; Vasilios G Gorgoulis; Ioannis Giotakis; Evangelos Tsiambas; Andreas Karameris; Christos Kittas; Aspasia Kyroudi
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

3.  Serum human telomerase reverse transcriptase: a novel biomarker for breast cancer diagnosis.

Authors:  Mahendar Porika; Radhika Tippani; Sekhar R Bollam; Sree Divya Panuganti; Christopher Thamidala; Sadanandam Abbagani
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

4.  Change of telomerase activity in peripheral blood of patients with head and neck squamous cell carcinoma pre and post curative treatment.

Authors:  M S Ganesh; Geeta S Narayanan; Rishabh Kumar
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-01

Review 5.  Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.

Authors:  Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.